Valneva Austria GmbH
Clinical Trials
53
Trial Phases
5 Phases
Drug Approvals
8
Clinical Trials
Distribution across different clinical trial phases (45 trials with phase data)• Click on a phase to view related trials
Assessment of Chikungunya Virus Seroprevalence Before VLA1553 Vaccination in the Municipalities Selected for Participation in the VLA1553 Pilot Vaccination Strategy in Brazil
- Conditions
- Chikungunya Virus Infection
- First Posted Date
- 2025-09-09
- Last Posted Date
- 2025-09-25
- Lead Sponsor
- Valneva Austria GmbH
- Target Recruit Count
- 4988
- Registration Number
- NCT07163845
- Locations
- 🇧🇷
Universidade Federal Do Ceará, Fortaleza, Ceará, Brazil
🇧🇷Universidade Federal de Minas Gerais, CT Terapias Avançadas e Inovadoras, Belo Horizonte, Minas Gerais, Brazil
🇧🇷Centro de Pesquisas Clínicas Universidade Federal Sergipe, Hospital e Maternidade São João de Deus, Laranjeiras, Sergipe, Brazil
A Trial to Evaluate the Safety and Immunogenicity of VLA1553 in Healthy Children
- Conditions
- Chikungunya Virus Infection
- Interventions
- Biological: Control
- First Posted Date
- 2025-08-20
- Last Posted Date
- 2025-09-15
- Lead Sponsor
- Valneva Austria GmbH
- Target Recruit Count
- 3000
- Registration Number
- NCT07133178
Phase 1 Trial to Assess the Safety and Immunogenicity of an Inactivated, Adjuvanted Whole Zika Virus Vaccine Candidate (VLA1601) in Healthy Adults
- Conditions
- ZikaZika Virus Infection
- Interventions
- First Posted Date
- 2024-03-28
- Last Posted Date
- 2025-08-19
- Lead Sponsor
- Valneva Austria GmbH
- Target Recruit Count
- 150
- Registration Number
- NCT06334393
- Locations
- 🇺🇸
Flourish Research, Chicago, Illinois, United States
🇺🇸Velocity Clinical Research, Omaha, Nebraska, United States
A Phase 2 Clinical Trial of VLA1553 in Healthy Children Aged 1 to 11 Years
- Conditions
- Chikungunya Virus Infection
- Interventions
- Biological: VLA1553 full doseBiological: VLA1553 half doseBiological: Control
- First Posted Date
- 2023-10-30
- Last Posted Date
- 2025-08-08
- Lead Sponsor
- Valneva Austria GmbH
- Target Recruit Count
- 304
- Registration Number
- NCT06106581
- Locations
- 🇩🇴
Fundacion Dominicana de Perinatologia Fundacion Probebe, Santo Domingo, Gazcue, Dominican Republic
🇩🇴Instituto Dermatologico y Cirugia de la Piel "Dr Huberto Bogaert Diaz" IDCP, Santo Domingo, Dominican Republic
🇭🇳Inversiones en Investigacion Medica INVERIME, Tegucigalpa, Honduras
A Clinical Phase 3 Trial of VLA1553 in Adult Participants with Human Immunodeficiency Virus (HIV)
- First Posted Date
- 2023-09-08
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Valneva Austria GmbH
- Target Recruit Count
- 75
- Registration Number
- NCT06028841
- Prev
- 1
- 2
- 3
- 4
- 5
- 9
- Next
News
VLA1553 Chikungunya Vaccine Shows Durable Antibody Response at Two Years
A phase 3b trial of VLA1553 showed that chikungunya virus-neutralizing antibodies persisted for up to two years post-vaccination.